1. 1. recognizing dna for therapy and diagnostics . Andrey Golovin June 2, 2015 AptaNova LLC
2. 2. antibodies .
3. 3. therapeutic antibodies Antibody market will reach $60-80 bln at 2018 Russian market presented by import for 90% Drugs on market: Avastin, Rituxan, Herceptin, Mylotarg, Bexxar, Benlysta ... ... .. 2008 . 2010 . 2012 . 2018 . 50 . 100 . year . Market,$bln 2
4. 4. antibodies disadvantages immune response biogenic origin non unied synthesis delivery action is not regulated (antidote is unavailable) 3
5. 5. aptamers .
6. 6. aptamer . Aptamers are articial molecules of single-stranded DNA molecule Aptamers binds protein target with non-covalent bonds on base of surface complementarity. low immune response unied chemical synthesis action is regulated (antidote is available) sensor element 5
7. 7. aptamers for theranostics .. Cancer . Virus . Vasicular . Aptamers targets . Drugs . Tuberculosis . Amilloids . Therapy 6
8. 8. our achievements .
9. 9. our approach .. Development and modelling . Animal testing . Synthesis and purication . 8
10. 10. our result: aptamer to thrombin .... in vitro . in vivo , mouse . certied trials 3 patents acquired and NO monkeys were harmed ! 9
11. 11. aptamer . Aptamer Thrombin Fibrin 10
12. 12. ra-36 usage .. Conservation . Heart surgery . Brain surgery . RA-36 usage . Pregnancy problems . Hemorrhoid . Clot therapy 11
13. 13. our plans .
14. 14. our plans We need 250 mln rubles We will set up production 70 + 100 mln rubles We will start 1st stage clinical trial 80 mln rubles 13
15. 15. future development ..Our approach. Anti-proliration aptamer development . Multiple target aptasensor chip 14
16. 16. team Science: 3 D.Sc. , 8 Ph.D. in chemistry and biology Managers: director, accounting, supply. Partners: Lomonosov MSU RAS Burdenko neurosurgery 15